ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 156 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $118,591 | -90.1% | 10,617 | -80.9% | 0.00% | – |
| Q2 2023 | $1,192,450 | -86.8% | 55,722 | -75.0% | 0.00% | -100.0% |
| Q1 2023 | $9,006,312 | +250.2% | 222,708 | +302.9% | 0.00% | – |
| Q4 2022 | $2,571,485 | +12.9% | 55,277 | +25.9% | 0.00% | – |
| Q3 2022 | $2,277,000 | +281.4% | 43,907 | +247.5% | 0.00% | – |
| Q2 2022 | $597,000 | -77.8% | 12,634 | -66.5% | 0.00% | – |
| Q1 2022 | $2,687,000 | +93.3% | 37,748 | +103.0% | 0.00% | – |
| Q4 2021 | $1,390,000 | +194.5% | 18,594 | +123.5% | 0.00% | – |
| Q3 2021 | $472,000 | +48.9% | 8,321 | +15.3% | 0.00% | – |
| Q2 2021 | $317,000 | -18.9% | 7,217 | -8.7% | 0.00% | – |
| Q1 2021 | $391,000 | +24.5% | 7,908 | +6.2% | 0.00% | – |
| Q4 2020 | $314,000 | -20.9% | 7,446 | -14.0% | 0.00% | – |
| Q3 2020 | $397,000 | -33.3% | 8,663 | -26.8% | 0.00% | – |
| Q2 2020 | $595,000 | -62.4% | 11,830 | -61.6% | 0.00% | – |
| Q1 2020 | $1,583,000 | +148.5% | 30,784 | +198.5% | 0.00% | – |
| Q4 2019 | $637,000 | -9.5% | 10,313 | -11.8% | 0.00% | – |
| Q3 2019 | $704,000 | -80.0% | 11,696 | -72.0% | 0.00% | -100.0% |
| Q2 2019 | $3,525,000 | +25.9% | 41,785 | +42.6% | 0.00% | – |
| Q1 2019 | $2,799,000 | +401.6% | 29,302 | +272.0% | 0.00% | – |
| Q4 2018 | $558,000 | -13.1% | 7,876 | +4.9% | 0.00% | – |
| Q3 2018 | $642,000 | -57.0% | 7,507 | -41.7% | 0.00% | – |
| Q2 2018 | $1,492,000 | -8.0% | 12,868 | -35.7% | 0.00% | – |
| Q1 2018 | $1,621,000 | +73.4% | 20,023 | +25.6% | 0.00% | – |
| Q4 2017 | $935,000 | -7.1% | 15,945 | -25.9% | 0.00% | – |
| Q3 2017 | $1,007,000 | +34.4% | 21,521 | +3.4% | 0.00% | – |
| Q2 2017 | $749,000 | -54.5% | 20,818 | -61.1% | 0.00% | – |
| Q1 2017 | $1,647,000 | +158.2% | 53,474 | +180.8% | 0.00% | – |
| Q4 2016 | $638,000 | +301.3% | 19,045 | +217.1% | 0.00% | – |
| Q3 2016 | $159,000 | -96.6% | 6,006 | -97.2% | 0.00% | -100.0% |
| Q2 2016 | $4,720,000 | -50.9% | 214,085 | -34.5% | 0.00% | -50.0% |
| Q1 2016 | $9,605,000 | -2.5% | 327,032 | +9.6% | 0.00% | 0.0% |
| Q4 2015 | $9,852,000 | -15.6% | 298,360 | -7.6% | 0.00% | -33.3% |
| Q3 2015 | $11,668,000 | +1252.0% | 322,858 | +1582.3% | 0.00% | – |
| Q2 2015 | $863,000 | +364.0% | 19,191 | +216.4% | 0.00% | – |
| Q1 2015 | $186,000 | -49.3% | 6,066 | -15.8% | 0.00% | – |
| Q4 2014 | $367,000 | +20.7% | 7,201 | -6.2% | 0.00% | – |
| Q3 2014 | $304,000 | +7500.0% | 7,680 | +7657.6% | 0.00% | – |
| Q2 2014 | $4,000 | -85.2% | 99 | -85.2% | 0.00% | – |
| Q1 2014 | $27,000 | -66.2% | 668 | -77.2% | 0.00% | – |
| Q4 2013 | $80,000 | +7900.0% | 2,935 | +11188.5% | 0.00% | – |
| Q3 2013 | $1,000 | -98.8% | 26 | -99.5% | 0.00% | – |
| Q2 2013 | $86,000 | – | 4,875 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |